RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

1) Yes, but he gave the OK to SP running an ADHD trial with Org26576. No artifact=no problem that I would foresee with CX-1739.
2) Cortex was cutting all expenses to the bone--now they have the money to do their compound stability studies. They couldnt afford it before.
3) BTW--I left out Lundbeck from the roster of companies interested in AMPA approaches to sz.
4) I'm not certain which study MV was referring to. Here is a Yale study which used both Lilly and Pfizer compounds to correct working memory deficits associated with the ketamine sz model--I think he was referring to animal data:
<< Behav Brain Res. 2010 Mar 25. [Epub ahead of print]
Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction.

Roberts BM, Holden DE, Shaffer CL, Seymour PA, Menniti FS, Schmidt CJ, Williams GV, Castner SA.

Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510; VA Connecticut Healthcare System, West Haven, CT 06519.

Working memory impairments are a core aspect of schizophrenia, yet current medicines do not address such cognitive dysfunction. We have developed a model of these working memory deficits by acutely disrupting glutamatergic synaptic transmission by administration of the N-methyl-D-aspartate (NMDA) antagonist ketamine in the nonhuman primate. The current studies evaluated the effect of positive allosteric modulators (“potentiators”) of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors on the working memory and behavioral effects of ketamine. AMPA receptors mediate fast excitatory synaptic transmission throughout the brain and play a critical role in the activity-dependent regulation of NMDA receptors. We find that positive modulation of AMPA receptors with LY451646 (0.1-1.0mg/kg, SC) and structurally-distinct PF-4778574 (0.01mg/kg, SC) robustly ameliorates ketamine-induced working memory impairments without altering behavioral effects of acute ketamine we consider related to positive- and negative-like symptoms. These results support AMPA receptor potentiators as a potential adjunctive treatment for cognitive impairment associated with schizophrenia (CIAS). >>

NeuroInvestment